|
Title
|
|
|
|
EV-301 long-term outcomes : 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Introduction: This exploratory analysis evaluated efficacy and safety data for enfortumab vedotin versus chemotherapy over a median follow-up of < |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Annals of oncology / European Society for Medical Oncology. - Amsterdam
|
|
|
Publication
|
|
|
|
Amsterdam
:
2023
|
|
|
ISSN
|
|
|
|
0923-7534
|
|
|
DOI
|
|
|
|
10.1016/J.ANNONC.2023.08.016
|
|
|
Volume/pages
|
|
|
|
34
:11
(2023)
, p. 1047-1054
|
|
|
ISI
|
|
|
|
001125042600001
|
|
|
Pubmed ID
|
|
|
|
37678672
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|